SEC EDGARAUG 241 min read$DXCM

SAYER KEVIN R sold $2.4M of DXCM

SAYER KEVIN R (Executive Chair) sold 26,756 shares of DEXCOM INC (DXCM) at an average of $90.01 ($89.71–$91.41, $2.41M total) across 3 trades on 2026-08-20 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · SAYER KEVIN R

Published Aug 24, 2026, 8:01 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 24, 2026, 8:23 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$DXCM

Bearish

medium confidence

Mentioned

$DXCM

Relevance

5/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$DXCMBearishLow

Why it matters

The disclosed sale adds new information for traders evaluating Dexcom's short‑term outlook.

Market read

Insider sale is a primary disclosure that may influence short‑term price action.

What to watch

Potential upcoming product announcements or earnings could offset the sale impact.

Relevance 5/10Novelty 5/10Timing: filing disclosed on 2026‑08‑24

Background

Form 4 filings provide the first public record of insider transactions.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$DXCMBearishMedium confidence

Context

Executive Chair Kevin Sayer sold 26,756 shares for $2.4M via a 10b5‑1 plan on 2026‑08‑20.

Expected impact

Potential modest dip in DXCM price over the next few days.

Evidence & confidence

Sale size is notable for an executive but not large enough to drive a major move; market may price in a slight bearish bias.

Market effects

Sector

Minimal impact on the broader medical device sector.

Regional

No significant regional effect.

Global

Limited to investors tracking Dexcom.

Counterpoint

What could challenge this read

The sale could be routine liquidity management, not a negative signal.

Key entities

Company
Dexcom Inc.
US‑listed medical device maker (ticker DXCM).
Individual
Kevin Sayer
Executive Chair of Dexcom, insider reporter.

Read at source ← All news

SEP 4

$PODDMedAI 8/10

Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks

Insulet (PODD) reported Q2 revenue of $801.7M, up 23.5% YoY, beating estimates by 1.9% but missing next quarter's guidance. Peers iRhythm (IRTC), ResMed (RMD), and DexCom (DXCM) also reported earnings, with mixed market reactions. PODD is down 11.6% since reporting, while DXCM is up 20.6%.

finance.yahoo.com3 min

SEP 3

$IRTCMed

Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks

iRhythm (IRTC) reported Q2 revenue of $224.2M, up 20.1% YoY, beating estimates. ResMed (RMD) reported $1.46B in revenue, up 8.6% YoY, in line with expectations. Insulet (PODD) reported $801.7M in revenue, up 23.5% YoY, beating estimates but missing guidance. IRTC stock is down 4.4%, RMD up 3.4%, and PODD down 11.6% since reporting.

finance.yahoo.com2 min

AUG 27

$ABTMedAI 8/10

The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?

Abbott Laboratories (NYSE: ABT) received FDA De Novo authorization for Libre Duo, a wearable that monitors glucose and detects rising ketone levels. The company plans a U.S. launch in 2026. Abbott's stock is down 11.29% over the past year but up 9.2% over the past month. The FDA approval is a regulatory milestone but may not immediately impact revenue.

247wallst.com4 min

AUG 21

$DXCMHighAI 8/10

DexCom stock hits 52-week high at 91.99 USD

DexCom Inc (DXCM) stock reached a 52-week high of $92.01, with a 36% year-to-date return. The company reported Q2 revenue of $1.308B, up 13% YoY, and raised its financial guidance. Analysts increased price targets, with Piper Sandler setting a $95 target. DexCom's inclusion in the FDA's TEMPO program and a perfect Piotroski Score of 9 indicate strong financial health.

investing.com2 min

AUG 21

$DXCMHighAI 9/10

DexCom posts $1.31B quarter as Silvant Capital opens a $5.4M stake

DexCom reported Q2 2026 revenue of $1.31B, up 13.1% YoY, and EPS of $0.70, beating estimates. Silvant Capital bought a $5.4M stake, while insiders sold shares. Analysts maintain 'buy' ratings with targets up to $93. The stock trades near its 12-month high.

app.dealroom.co2 min

AUG 14

$DXCMMed

Is Wall Street Bullish or Bearish on DexCom Stock?

DexCom (DXCM) designs continuous glucose monitoring systems. The stock lagged the S&P 500 and XLV over 52 weeks but gained 37.2% YTD. After Q2 2026 results on Jul. 30, adjusted EPS was $0.70 and revenue $1.31B, up 13% YoY, beating estimates. DexCom raised 2026 revenue guidance to $5.18B-$5.25B. Canaccord lifted its price target to $90; mean target $92.48.

barchart.com4 min